Cargando…

RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling

Endogenous satiety hormones provide an attractive target for obesity drugs. Glucagon causes weight loss by reducing food intake and increasing energy expenditure. To further understand the cellular mechanisms by which glucagon and related ligands activate the glucagon receptor (GCGR), we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cegla, Jaimini, Jones, Ben J., Gardiner, James V., Hodson, David J., Marjot, Thomas, McGlone, Emma R., Tan, Tricia M., Bloom, Stephen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551549/ https://www.ncbi.nlm.nih.gov/pubmed/28586439 http://dx.doi.org/10.1210/en.2016-1755

Ejemplares similares

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2021)

Hepatocyte cholesterol content modulates glucagon receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2022)

Loading and Unloading Weaned Pigs: Effects of Bedding Types, Ramp Angle, and Bedding Moisture
por: Garcia, Arlene, et al.
Publicado: (2014)

Loading and Unloading Finishing Pigs: Effects of Bedding Types, Ramp Angle, and Bedding Moisture
por: Garcia, Arlene, et al.
Publicado: (2014)

The Effects of Using a Ramp and Elevator to Load and Unload Trailers on the Behavior and Physiology of Piglets
por: McGlone, John, et al.
Publicado: (2014)

Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
por: Weston, Cathryn, et al.
Publicado: (2015)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors
por: Jones, Ben, et al.
Publicado: (2020)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Modulating effects of RAMPs on signaling profiles of the glucagon receptor family
por: Shao, Lijun, et al.
Publicado: (2022)

Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor
por: Jones, Ben J., et al.
Publicado: (2017)

Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
por: Fang, Zijian, et al.
Publicado: (2020)

A glucagon analogue decreases body weight in mice via signalling in the liver
por: Hinds, Charlotte E., et al.
Publicado: (2021)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
por: Marzook, Amaara, et al.
Publicado: (2021)

The use of whole blood capillary samples to measure 15 analytes for a home-collect biochemistry service during the SARS-CoV-2 pandemic: A proposed model from North West London Pathology
por: Ansari, Saleem, et al.
Publicado: (2021)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
por: Pickford, Phil, et al.
Publicado: (2021)

Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”
por: Müller, Timo D., et al.
Publicado: (2020)

Orbit in the ramp
por: Wenninger, J
Publicado: (1998)

Pharmacological Differences between Human and Rat CGRP Receptors Are Determined by RAMP1
por: Kane, S., et al.
Publicado: (2001)

Lp(a): When and how to measure it
por: Cegla, Jaimini, et al.
Publicado: (2020)

Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
por: Scott, R., et al.
Publicado: (2018)

The effects of dyslipidaemia and cholesterol modulation on erythrocyte susceptibility to malaria parasite infection
por: Koch, Marion, et al.
Publicado: (2019)

3rd Expert Consultation on RAMP : RAMP-III
Publicado: (1986)

Ramp Management in RHIC
por: Kewisch, J, et al.
Publicado: (1999)

Injection and ramping: Discussion
por: Wenninger, J
Publicado: (1998)

Ramping high intensities
por: Wenninger, J
Publicado: (1997)

Ramping High Currents
por: Wenninger, J
Publicado: (1999)

Energy ramping in LEP
por: Ciapala, Edmond, et al.
Publicado: (1990)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
por: Tan, Tricia M., et al.
Publicado: (2013)

Injection and ramping summary
por: Lamont, M, et al.
Publicado: (1997)

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
por: Hope, David C.D., et al.
Publicado: (2022)

Ramping '97
por: Jonker, M
Publicado: (1998)

Accumulation and ramping
por: Brüning, Oliver Sim
Publicado: (2000)

Ramping and snapback
por: Butterworth, A
Publicado: (2005)

Collision tunes at injection and ramp
por: Calaga, R, et al.
Publicado: (2011)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Problem or solution: The strange story of glucagon
por: Scott, R.V., et al.
Publicado: (2018)

Derivation and comparison of formulae for the adjustment of total calcium
por: Phylactou, Maria, et al.
Publicado: (2023)

Losses of Protons during the Ramp
por: Sen, T, et al.
Publicado: (2003)

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s3qk4pi9q1onn0memkab9ouupd